For past 6 years, the team has shown outstanding performance, such as 164 SCI theses, 15 registered patents, 2 technology transfers.
The Team developed anti-high blood pressure, anti-aging, and anti-cancer improved new drugs, and prepared for their commercialization.
[October 17, 2012]

 YU (president Lee, Hyo-soo) received 'very good' rating for the overall evaluations of the 2nd phase 'Research-oriented University Fostering Project' (Brain Korea 21, hereinafter 'BK21')

 Recently, the Ministry of Education, Science and Technology(MEST), and the National Research Foundation of Korea announced the results of analyzing and assessing the performance of the 500 project units (teams) of 65 universities nationwide that received support for the 2nd phase BK 21 project from 2006 to 2012. According to the results, the YU College of Pharmacy's 'Improved New Drug Development and Efficacy Evaluation Human Resource Fostering Team' (team leader Yong, Chul-soon, hereinafter 'Improved New Drug Team' received the highest rating.

 4 professors such as Yong, Chul-soon and Kim, Jong-oh (improved new drug development) and Kim, Jung-ae and Park, Pil-hoon (efficacy evaluation) and 91 graduate school students (average 12 students per year) participated in YU's 'New Improved Drug Team' and published 164 SCI-level theses in the past 6 years. Basically, 27.3 SCI-level theses were published a year and 2.3 a month. In addition, the graduate school was specialized in order to foster and supply outstanding researchers customized to local companies. Thus, it was assessed to be a successful case that offered a systematic cornerstone and stable establishment of the research-oriented university fostering project by newly graduating 5 doctorates and 33 masters.

 The YU Improved New Drug Team displayed outstanding performance in the new technology development and technology transfer sector as well. For the past 6 years, it applied for 27 domestic patents and registered 15, while also transferring technologies for 2 improved new drugs through continuous industry-university cooperation and joint research with related businesses such as Dong-A Pharmaceutical and TG Biotech, thus having considerable effects in generating business. It has developed improved new medicines for anti-high blood pressure, anti-aging, and anti-cancer, and is currently in the process of commercializing them.

 On this, Professor Yong, Chul-soon (School of Pharmacy, 56), the leader of the Improved New Drug Team, stated, "The BK21 Project Assessment is an overall assessment of the performance for the past 6 years, and is meaningful because it is the last assessment for the BK21 that will end in February 2013." He added, "With the domestic pharmaceutical industry that was focused more on generic drugs being reorganized to be improved new drug-oriented, we will concentrate on fostering the best brains of universities so that it can become competitive in the global market as well."

 Meanwhile, the second phase BK21 Project supports graduate school students and up-and-coming researchers (post-doc, etc) in order to foster world-class research-oriented university and outstanding local graduate schools, and to foster high quality R&D personnel. The YU Improved New Drug Team is planning to participate in the Performance Exhibit hosted by the National Research Foundation of Korea at the Gwacheon National Science Museum on the 23rd and 24th to contribute to proliferation of the research results.